Biologic, demographic, and social factors affecting triple negative breast cancer outcomes.

BACKGROUND Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that disproportionately affects women who are African American, younger, or carriers of the BRCA1 gene. No targeted treatments exist for the disease, which has distinct features and presents unique challenges to patients who have been diagnosed with it. OBJECTIVES TNBC is reviewed in this article according to incidence, tumor grade, stage of diagnosis, biologic and social risk factors, mortality, and treatment. METHODS Published articles pertaining to TNBC and located through online database searches were reviewed. Articles were selected either because they offered the most current information about TNBC or contributed to the understanding of TNBC. FINDINGS Biologic, demographic, and social factors present unique challenges in the treatment of women with TNBC. Knowing about the characteristics of TNBC and the populations who are most at risk for the disease might help healthcare providers better respond to their patients. It may also facilitate responsiveness to patients' needs and enhance their quality of life.

[1]  T. Kolevska,et al.  Effect of medical oncologists' attitudes on accrual to clinical trials in a community setting. , 2013, Journal of oncology practice.

[2]  E. Fisher,et al.  Coaching intervention as a strategy for minority recruitment to cancer clinical trials. , 2013, Journal of oncology practice.

[3]  L. Siminoff,et al.  Perceptions of participation in a phase I, II, or III clinical trial among African American patients with cancer: what do refusers say? , 2013, Journal of oncology practice.

[4]  W. McCaskill-Stevens,et al.  The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. , 2013, Journal of oncology practice.

[5]  M. Knobf,et al.  Being prepared: essential to self-care and quality of life for the person with cancer. , 2013, Clinical journal of oncology nursing.

[6]  K. Hess,et al.  The prognostic impact of age in patients with triple-negative breast cancer , 2013, Breast Cancer Research and Treatment.

[7]  D. Yardley,et al.  Updates in the treatment of basal/triple-negative breast cancer , 2013, Current Opinion in Obstetrics and Gynecology.

[8]  K. Pogoda,et al.  Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients , 2013, Medical Oncology.

[9]  G. Guler,et al.  Lymphatic and Capillary Invasion Patterns in Triple Negative Breast Cancer , 2012, The American surgeon.

[10]  P. Neven,et al.  Update on triple-negative breast cancer: prognosis and management strategies , 2012, International journal of women's health.

[11]  C. Sotiriou,et al.  Understanding the biology of triple-negative breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Crown,et al.  Emerging targeted therapies in triple-negative breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Echenique,et al.  Triple negative breast cancer: a retrospective study of Hispanics residing in Puerto Rico. , 2012, Puerto Rico health sciences journal.

[14]  Paul Ellis,et al.  Dissecting the heterogeneity of triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Salner,et al.  Needs assessment of cancer survivors in Connecticut , 2012, Journal of Cancer Survivorship.

[16]  P. O'Brien,et al.  Obstacles to participation in randomised cancer clinical trials: A systematic review of the literature , 2012, Journal of medical imaging and radiation oncology.

[17]  Xi Chen,et al.  TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer , 2012, Cancer informatics.

[18]  A. González-Angulo,et al.  Triple‐negative breast cancer in Hispanic patients , 2011, Cancer.

[19]  A. Richardson,et al.  The experiences, needs and concerns of younger women with breast cancer: a meta‐ethnography , 2011, Psycho-oncology.

[20]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[21]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[22]  L. Newman,et al.  Higher population‐based incidence rates of triple‐negative breast cancer among young African‐American women , 2011, Cancer.

[23]  A. Kurian,et al.  Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups , 2010, Breast Cancer Research.

[24]  L. Newman,et al.  African ancestry and higher prevalence of triple‐negative breast cancer , 2010, Cancer.

[25]  R. Chacón,et al.  Triple-negative breast cancer , 2010, Breast Cancer Research.

[26]  B. Pockaj,et al.  Triple-Negative Breast Cancers: Unique Clinical Presentations and Outcomes , 2010, Annals of Surgical Oncology.

[27]  Scott D Ramsey,et al.  A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. , 2010, Journal of the National Cancer Institute.

[28]  Harold L. Moses,et al.  A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program , 2010 .

[29]  R. Shi,et al.  Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. , 2010, Breast.

[30]  E. Garrett-Mayer,et al.  Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status , 2010, Cancer Causes & Control.

[31]  B. Polite,et al.  Triple-Negative Breast Cancers: A View From 10,000 Feet , 2010, Cancer journal.

[32]  Seema A Khan,et al.  NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[33]  C. Perou,et al.  Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  O. Dizdar,et al.  Pharmacotherapy of triple-negative breast cancer , 2009, Expert opinion on pharmacotherapy.

[35]  R. Coates,et al.  The epidemiology of triple-negative breast cancer, including race , 2009, Cancer Causes & Control.

[36]  T. Lash,et al.  Triple-negative breast cancers are increased in black women regardless of age or body mass index , 2009, Breast Cancer Research.

[37]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Linda G. Kimmel,et al.  Physician-related factors involved in patient decisions to enroll onto cancer clinical trials. , 2009, Journal of oncology practice.

[39]  L. Esserman,et al.  Hypertension is an independent predictor of survival disparity between African‐American and white breast cancer patients , 2009, International journal of cancer.

[40]  G. Hobbs,et al.  Triple-Negative Breast Cancer and Obesity in a Rural Appalachian Population , 2008, Cancer Epidemiology Biomarkers & Prevention.

[41]  G. Hortobagyi,et al.  Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women , 2008, Breast Cancer Research and Treatment.

[42]  T. Naab,et al.  Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women. , 2008, American journal of surgery.

[43]  Lyndsay N Harris,et al.  Triple negative breast cancer: current understanding of biology and treatment options , 2008, Current opinion in obstetrics & gynecology.

[44]  Richard L. Street,et al.  Patient-centered communication in cancer care: Promoting healing and reducing suffering , 2007 .

[45]  Suzanne M. Miller,et al.  Barriers to clinical trial participation as perceived by oncologists and patients. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[46]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[47]  D. Schrag,et al.  Missed opportunities: racial disparities in adjuvant breast cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Knobf,et al.  The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. , 2006, The oncologist.

[49]  Kumanan Wilson,et al.  Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. , 2006, The Lancet. Oncology.

[50]  A. Neugut,et al.  Racial disparities in treatment and survival among women with early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  S. Kasl,et al.  Inadequate Follow-up of Abnormal Screening Mammograms: Findings From the Race Differences in Screening Mammography Process Study (United States) , 2005, Cancer Causes & Control.

[52]  B. Falkner,et al.  Race/ethnic issues in obesity and obesity-related comorbidities. , 2004, The Journal of clinical endocrinology and metabolism.

[53]  P. Ganz,et al.  Breast cancer in younger women: reproductive and late health effects of treatment. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  V. Parker,et al.  Inner resources as predictors of psychological well-being in middle-income african american breast cancer survivors. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[55]  M. Wilmoth,et al.  Accept me for myself: African American women's issues after breast cancer. , 2001, Oncology nursing forum.

[56]  N. Lackey,et al.  African American women's experiences with the initial discovery, diagnosis, and treatment of breast cancer. , 2001, Oncology nursing forum.

[57]  M. Coovert,et al.  Strategic physician communication and oncology clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[59]  P. Fumoleau,et al.  The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment , 2012, The breast journal.

[60]  C. Hudis,et al.  Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.

[61]  M. Roizen.  Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients , 2010 .

[62]  R. Coates,et al.  Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA , 2008, Breast Cancer Research and Treatment.

[63]  B. Davis,et al.  African American women coping with breast cancer: a qualitative analysis. , 2003, Oncology nursing forum.

[64]  R. Carlson.  NCCN breast cancer clinical practice guidelines in oncology: an update. , 2003, Journal of the National Comprehensive Cancer Network : JNCCN.